Clinical Trial

A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab

Study acronym: BIFANG
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.
Protocol Amendment History 7 changes
notable Trial sites expanded: 21 -> 39 locations 2026-08-15
notable Trial sites reduced: 33 -> 21 locations 2026-08-13
notable Trial sites expanded: 21 -> 33 locations 2026-07-11
notable Trial sites expanded: 1 -> 21 locations 2026-06-25
critical Recruitment opened 2026-05-27
notable Trial sites reduced: 51 -> 1 locations 2026-05-27
minor Completion moved earlier: 2028-08-15 -> 2028-03-07 2026-05-27
Trial Details
NCT Number NCT07520162
Lead Sponsor AstraZeneca
Conditions Chronic Rhinosinusitis With Nasal Polyps
Enrollment 230 participants
Start Date 2026-04-24
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-03-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-14